GC Biopharma Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de GC Biopharma ont diminué à un taux annuel moyen de -18.8%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 1.6% par an. Les revenus ont augmenté de en à un taux moyen de 4.2% par an.

Informations clés

-18.8%

Taux de croissance des bénéfices

-10.7%

Taux de croissance du BPA

Biotechs Croissance de l'industrie	11.7%
Taux de croissance des recettes	4.2%
Rendement des fonds propres	-1.5%
Marge nette	-1.1%
Dernière mise à jour des bénéfices	30 Sep 2024

Mises à jour récentes des performances passées

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Recent updates

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Nov 19

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Nov 07

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Ventilation des recettes et des dépenses

Comment GC Biopharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

KOSE:A006280 Recettes, dépenses et bénéfices (KRW Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
30 Sep 24	1,643,983	-18,855	260,160	153,701
30 Jun 24	1,618,467	-38,195	260,990	155,203
31 Mar 24	1,633,972	-29,491	261,692	161,699
31 Dec 23	1,626,644	-26,632	262,217	173,487
30 Sep 23	1,633,172	1,858	280,061	191,908
30 Jun 23	1,653,489	25,441	283,991	200,965
31 Mar 23	1,643,852	36,611	291,422	205,175
31 Dec 22	1,711,313	65,453	295,284	191,347
30 Sep 22	1,702,128	108,541	297,800	180,583
30 Jun 22	1,708,169	124,737	298,750	173,838
31 Mar 22	1,672,535	114,840	298,563	151,949
31 Dec 21	1,537,826	123,212	289,761	146,030
30 Sep 21	1,552,271	86,257	277,318	146,836
30 Jun 21	1,506,143	93,472	266,822	136,059
31 Mar 21	1,478,566	99,854	247,721	138,285
31 Dec 20	1,504,115	80,886	243,368	137,987
30 Sep 20	1,438,540	44,131	229,689	124,886
30 Jun 20	1,385,465	7,169	219,727	123,136
31 Mar 20	1,381,597	-8,068	207,686	125,411
31 Dec 19	1,357,117	1,341	195,548	126,673
30 Sep 19	1,352,625	21,663	178,769	123,265
30 Jun 19	1,338,420	14,322	172,058	125,012
31 Mar 19	1,324,106	23,943	169,005	124,159
31 Dec 18	1,334,878	34,429	167,043	122,029
30 Sep 18	1,314,527	32,485	167,922	121,125
30 Jun 18	1,318,285	42,928	167,117	117,807
31 Mar 18	1,306,606	64,339	164,046	112,764
31 Dec 17	1,287,916	53,247	161,412	108,639
30 Sep 17	1,282,593	76,100	155,259	112,519
30 Jun 17	1,254,113	71,435	153,044	113,156
31 Mar 17	1,227,485	62,300	154,949	113,861
31 Dec 16	1,197,904	62,970	154,677	112,283
30 Sep 16	1,146,958	40,707	155,375	112,607
30 Jun 16	1,114,394	75,617	151,820	104,441
31 Mar 16	1,079,274	87,817	146,660	100,021
31 Dec 15	1,047,812	94,967	142,875	98,210
30 Sep 15	1,035,748	96,613	139,435	86,319
30 Jun 15	1,023,133	84,250	136,491	82,718
31 Mar 15	990,420	68,220	132,621	77,561
31 Dec 14	975,327	83,945	131,217	76,990
30 Sep 14	959,764	86,914	124,781	76,210
30 Jun 14	937,735	75,576	122,349	77,998
31 Mar 14	908,456	79,108	119,907	76,388
31 Dec 13	888,168	70,066	117,396	73,615

Des revenus de qualité: A006280 n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: A006280 n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: A006280 n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 18.8% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de A006280 au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: A006280 n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( -1.3% ).

Rendement des fonds propres

ROE élevé: A006280 a un retour sur capitaux propres négatif ( -1.48% ), car il n'est actuellement pas rentable.

GC Biopharma Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Full year 2022 earnings: EPS exceeds analyst expectations

First quarter 2022 earnings: Revenues exceed analyst expectations

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Recent updates

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

New 90-day high: ₩505,000

GC Pharma and Clinigen K.K. Announces Marketing Approval for Hunterase ICV Injection 15 mg

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

New 90-day high: ₩475,000

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Upcoming Dividend of ₩1,000 Per Share

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Analysts update estimates